Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nanobiotix Sa ADR (NBTX)
:NBTX
Holding NBTX?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.54Last Year’s EPS
-0.13Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 15, 2019
|% Change Since: -30.50%
|Next Earnings Date:Sep 04, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a generally positive outlook with significant achievements in collaboration with Janssen and advancement in clinical trials. However, challenges remain with extended timelines for critical trials and the necessity for additional funding. The strategic development of new platforms adds a forward-looking positive aspect to the company's trajectory.Company Guidance
During the Nanobiotix Q1 2024 earnings call, the company provided guidance on its financial and strategic progress, highlighting several key metrics. Nanobiotix reported an unaudited cash balance of EUR 58.9 million and reaffirmed its cash runway into Q3 2025. The company also highlighted a $20 million milestone payment received from Janssen, part of a collaboration potentially worth more than $2.5 billion plus royalties. This partnership aims to expand the global potential of their lead therapeutic candidate, NBTXR3, across various solid tumor indications. Additionally, Nanobiotix discussed the ongoing pivotal Phase III NANORAY-312 trial, which is evaluating NBTXR3 for elderly patients with locally advanced head and neck cancer. They also plan a randomized Phase II study for Stage 3 non-small cell lung cancer. The transfer of the NANORAY-312 trial sponsorship to Janssen is expected to facilitate global commercialization efforts. Furthermore, the company is exploring expansion opportunities in additional cancer settings and developing two additional nanoparticle platforms, Curadigm and Oocuity, with updates expected in the second half of 2024.Strong Cash Position
Announced a first quarter 2024 unaudited cash balance of EUR 58.9 million and reaffirmed cash runway into Q3 2025.
Significant Progress with Janssen Collaboration
Achieved significant progress in the Janssen collaboration for NBTXR3, including a $20 million milestone payment and positive developments in regulatory and manufacturing processes.
Advance in NANORAY-312 Trial
Positive top line data from the expansion part of the Study 102 for NBTXR3, leading to protocol amendments in the NANORAY-312 pivotal Phase III trial.
New Platforms Development
Introduced Curadigm and Oocuity platforms, aiming to expand nanoparticle-based therapy in healthcare.
---
NBTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NBTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $4.36 | $4.14 | -5.05% |
| Sep 18, 2024 | $4.93 | $5.32 | +7.91% |
| May 22, 2024 | $7.11 | $6.22 | -12.52% |
| Apr 24, 2024 | $5.90 | $5.91 | +0.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Nanobiotix Sa ADR (NBTX) report earnings?
Nanobiotix Sa ADR (NBTX) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Nanobiotix Sa ADR (NBTX) earnings time?
Nanobiotix Sa ADR (NBTX) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NBTX EPS forecast?
NBTX EPS forecast for the fiscal quarter 2024 (Q4) is -0.54.
---